Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture

被引:32
|
作者
Badolo, Lassina [1 ,2 ]
Jensen, Bente [1 ,2 ]
Sall, Carolina [1 ,2 ]
Norinder, Ulf [1 ,2 ]
Kallunki, Pekka [3 ]
Montanari, Dino [1 ,2 ]
机构
[1] H Lundbeck & Co AS, Discovery Chem, Copenhagen, Denmark
[2] H Lundbeck & Co AS, DMPK, Copenhagen, Denmark
[3] H Lundbeck & Co AS, Dept Neurodegenerat, Copenhagen, Denmark
关键词
Cytochrome P450; cryopreserved human hepatocytes; drug-drug interactions; hepatic transporters; induction; sandwich culture; DRUG-DRUG INTERACTIONS; CYTOCHROME-P450; ENZYMES; RAT HEPATOCYTES; INDUCTION; EXPRESSION; XENOBIOTICS; METABOLISM; RECEPTORS; TIME; TRANSPORTERS;
D O I
10.3109/00498254.2014.955831
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Regulation of hepatic metabolism or transport may lead to increase in drug clearance and compromise efficacy or safety. In this study, cryopreserved human hepatocytes were used to assess the effect of 309 compounds on the activity and mRNA expression (using qPCR techniques) of CYP1A2, CYP2B6 and CYP3A4, as well as mRNA expression of six hepatic transport proteins: OATP1B1 (SCLO1B1), OCT1 (SLC22A1), MDR1 (ABCB1), MRP2 (ABCC2), MRP3 (ABCC3) and BCRP (ABCG2). The results showed that 6% of compounds induced CYP1A2 activity (1.5-fold increase); 30% induced CYP2B6 while 23% induced CYP3A4. qPCR data identified 16, 33 or 32% inducers of CYP1A2, CYP2B6 or CYP3A4, respectively. MRP2 was induced by 27 compounds followed by MDR1 (16) > BCRP (9) > OCT1 (8) > OATP1B1 (5) > MRP3 (2). CYP3A4 appeared to be down-regulated (>= 2-fold decrease in mRNA expression) by 53 compounds, 10 for CYP2B6, 6 for OCT1, 4 for BCRP, 2 for CYP1A2 and OATP1B1 and 1 for MDR1 and MRP2. Structure-activity relationship analysis showed that CYP2B6 and CYP3A4 inducers are bulky lipophilic molecules with a higher number of heavy atoms and a lower number of hydrogen bond donors. Finally, a strategy for testing CYP inducers in drug discovery is proposed.
引用
收藏
页码:177 / 187
页数:11
相关论文
共 50 条
  • [1] The Roles of MRP2, MRP3, OATP1B1, and OATP1B3 in Conjugated Hyperbilirubinemia
    Keppler, Dietrich
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) : 561 - 565
  • [2] Determination of CYP1A2 and CYP3A4 induction in cryopreserved human hepatocytes
    Roymans, D
    Van Looveren, C
    Leone, A
    Parker, BJ
    McMillian, M
    Johnson, MD
    Koganti, A
    Silber, P
    Mannens, G
    Meuldermans, W
    DRUG METABOLISM REVIEWS, 2003, 35 : 71 - 71
  • [3] In situ evaluation of CYP1A2, CYP2B6 and CYP3A4/5 induction in human hepatocytes with a cocktail of probe substrates
    Amunom, Immaculate
    Brawner, Sarah
    Simpson, Jennifer
    Sawi, Janet
    Campbell, Rebecca
    Neat, Jason
    Parkinson, Andrew
    DRUG METABOLISM REVIEWS, 2009, 41 : 89 - 89
  • [4] OVERLAP AND DIFFERENCES IN THE INHIBITION OF HUMAN OATP1B1, OATP1B3, MDR1, AND MRP2 BY REGISTERED DRUGS IN VITRO
    Van de Steeg, Evita
    Vlaming, Maria L. H.
    Jansen, Harm T.
    Nooijen, Irene H. G.
    Schrander, Freek L.
    DeGroot, Jeroen
    Wortelboer, Heleen M.
    DRUG METABOLISM REVIEWS, 2012, 44 : 77 - 77
  • [5] Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers
    Liu, Lichuan
    Cui, Yunhai
    Chung, Alfred Y.
    Shitara, Yoshihisa
    Sugiyama, Yuichi
    Keppler, Dietrich
    Pang, K. Sandy
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (01): : 395 - 402
  • [6] Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes
    Runge, D
    Köhler, C
    Kostrubsky, VE
    Jäger, D
    Lehmann, T
    Runge, DM
    May, U
    Stolz, DB
    Strom, SC
    Fleig, WE
    Michalopoulos, GK
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (01) : 333 - 341
  • [7] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    M. I. Veiga
    S. Asimus
    P. E. Ferreira
    J. P. Martins
    I. Cavaco
    V. Ribeiro
    T. N. Hai
    M. G. Petzold
    A. Björkman
    M. Ashton
    J. P. Gil
    European Journal of Clinical Pharmacology, 2009, 65 : 355 - 363
  • [8] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    Veiga, M. I.
    Asimus, S.
    Ferreira, P. E.
    Martins, J. P.
    Cavaco, I.
    Ribeiro, V.
    Hai, T. N.
    Petzold, M. G.
    Bjorkman, A.
    Ashton, M.
    Gil, J. P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 355 - 363
  • [9] Regulation of mRNA expression of MDR1, MRP1, MRP2 and MRP3 by prototypical microsomal enzyme inducers in primary cultures of human and rat hepatocytes
    Nishimura, Masuhiro
    Koeda, Akiko
    Suzuki, Ernako
    Kawano, Yuichi
    Nakayama, Mitsuo
    Satoh, Tetsuo
    Narimatsu, Shizuo
    Naito, Shinsaku
    DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (04) : 297 - 307
  • [10] Differential induction of mdr1, mrp1, mrp2 and mrp3 carcinoma cell lines
    Huang, R
    Murry, DJ
    Kolwankar, D
    Foster, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 59 - 59